We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and General Motors among those reporting.

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find out why I rate MRK a Buy.

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck & Co., Inc is a global healthcare leader company engaged in the discovery, identification, and development of advanced treatment for cancer and various diseases.